CL2015002723A1 - Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23 - Google Patents

Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23

Info

Publication number
CL2015002723A1
CL2015002723A1 CL2015002723A CL2015002723A CL2015002723A1 CL 2015002723 A1 CL2015002723 A1 CL 2015002723A1 CL 2015002723 A CL2015002723 A CL 2015002723A CL 2015002723 A CL2015002723 A CL 2015002723A CL 2015002723 A1 CL2015002723 A1 CL 2015002723A1
Authority
CL
Chile
Prior art keywords
antibody
methods
treat psoriasis
psoriasis
treat
Prior art date
Application number
CL2015002723A
Other languages
English (en)
Spanish (es)
Inventor
Wayne Tsuji
John P Gibbs
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015002723A1 publication Critical patent/CL2015002723A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
CL2015002723A 2013-03-15 2015-09-15 Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23 CL2015002723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002723A1 true CL2015002723A1 (es) 2016-03-28

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002723A CL2015002723A1 (es) 2013-03-15 2015-09-15 Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23

Country Status (17)

Country Link
US (3) US20160060337A1 (enExample)
EP (2) EP2968488A1 (enExample)
JP (4) JP2016517408A (enExample)
KR (1) KR20150128858A (enExample)
CN (1) CN105209064A (enExample)
AP (1) AP2015008803A0 (enExample)
AU (3) AU2014238148A1 (enExample)
CA (1) CA2906382A1 (enExample)
CL (1) CL2015002723A1 (enExample)
CR (1) CR20150572A (enExample)
EA (1) EA201591581A1 (enExample)
HK (1) HK1219425A1 (enExample)
IL (2) IL241342A0 (enExample)
PH (2) PH12015502129A1 (enExample)
SG (2) SG10201804954UA (enExample)
TN (1) TN2015000403A1 (enExample)
WO (1) WO2014149425A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
IL307578A (en) 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
AU2017241776B2 (en) * 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
AU2017250583A1 (en) * 2016-04-15 2018-08-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2020016838A2 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
BR112021008582A8 (pt) * 2018-11-05 2023-02-07 Merck Sharp & Dohme Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
WO2020188466A1 (en) * 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
SG165322A1 (en) 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗il−23抗体、組成物、方法および用途
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
US20100111966A1 (en) * 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP2011515404A (ja) * 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法
CN102113185B (zh) 2008-06-30 2013-12-18 百得有限公司 用于电动工具的线保护器
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗il−23免疫グロブリン
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
AU2011311965A1 (en) * 2010-10-06 2013-03-28 Abbvie Inc. Methods for treating psoriasis
WO2012045848A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23

Also Published As

Publication number Publication date
US20200277368A1 (en) 2020-09-03
EP3689369A1 (en) 2020-08-05
JP2021102644A (ja) 2021-07-15
IL241342A0 (en) 2015-11-30
US20220135668A1 (en) 2022-05-05
US20160060337A1 (en) 2016-03-03
PH12015502129A1 (en) 2016-01-25
AU2020270495A1 (en) 2020-12-17
TN2015000403A1 (en) 2017-01-03
WO2014149425A1 (en) 2014-09-25
IL275093A (en) 2020-07-30
CR20150572A (es) 2016-04-25
JP2016517408A (ja) 2016-06-16
JP2023011815A (ja) 2023-01-24
SG11201507482UA (en) 2015-10-29
PH12019502700A1 (en) 2020-12-07
CA2906382A1 (en) 2014-09-25
AU2014238148A1 (en) 2015-10-08
SG10201804954UA (en) 2018-07-30
HK1219425A1 (zh) 2017-04-07
JP2020063237A (ja) 2020-04-23
EA201591581A1 (ru) 2016-01-29
AU2019200206A1 (en) 2019-01-31
AP2015008803A0 (en) 2015-10-31
CN105209064A (zh) 2015-12-30
KR20150128858A (ko) 2015-11-18
EP2968488A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CL2015002723A1 (es) Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
BR112015030351A2 (pt) método e aparelho para realização de transações locais
BR112015020236A2 (pt) método e aparelho para comunicação focalizada de dados
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
CL2015001929A1 (es) Sistema y método optico para seleccionar semillas
CL2017002728A1 (es) Método para el tratamiento de cáncer
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
ES2813450T8 (es) Compuestos y métodos para tratar un trastorno epiléptico
HUE049442T2 (hu) Módszerek eozinofil nyelõcsõgyulladás kezelésére IL-4R inhibitor beadásával
EP3022216C0 (en) IMPROVED PROCESS FOR ORGANIC SOLVENT TREATMENT OF LIGNOCELLULOSIC BIOMASS
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112013031968A2 (pt) método e aparelho para testes magnéticos
BR112016014327A2 (pt) método e aparelho para predição de tabela de paleta
BR112013028187A2 (pt) processo para produzir olefinas
BR112014000351A2 (pt) “método para tratamento prévio de biomassa lignocelulósica”
BR112013031795A2 (pt) método para tratar uma doença
IL266607A (en) A method for treating eczema with a specific anti-IL-23 antibody
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
EA201690990A1 (ru) Способы получения ингибиторов фосфатидилинозитол-3-киназы
UY34708A (es) Metodo para producir glicósidos de esteviol
BR112013024363A2 (pt) método, e aparelho
BR112013032218A2 (pt) método para coprodução de hidrocarbonetos
BR112013023227A2 (pt) método para tratar perda de circulação, e material de circulação perdida de gelificação (lcm)